Related references
Note: Only part of the references are listed.RESILIENT part 1: A phase 2 dose-exploration and dose-expansion study of second-line liposomal irinotecan in adults with small cell lung cancer
Luis Paz-Ares et al.
CANCER (2022)
Address for correspondence: Rimner, MDE-mail contact: rimnera@mskcc.org
Andreas Rimner et al.
CLINICAL LUNG CANCER (2022)
Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers
Song Qu et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study
Zsolt Megyesfalvi et al.
JOURNAL OF PATHOLOGY (2022)
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Jie Wang et al.
LANCET ONCOLOGY (2022)
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
Hirokazu Taniguchi et al.
CELL REPORTS (2022)
Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
Ying Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.
Antonio Calles et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC).
Jonathan W. Goldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death- Ligand 1 Blockade Resistance in SCLC
Evelyn M. Nguyen et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial
Ying Cheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer
H. Borghaei et al.
Journal of Thoracic Oncology (2022)
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
A. Gennari et al.
ANNALS OF ONCOLOGY (2021)
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis
Mingrui Zhu et al.
CANCER RESEARCH (2021)
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
Stephen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331
D. R. Spigel et al.
ANNALS OF ONCOLOGY (2021)
Small cell lung cancer enters the era of precision medicine
Kristopher K. Frese et al.
CANCER CELL (2021)
PL02.03 Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
L. Paz-Ares et al.
Journal of Thoracic Oncology (2021)
Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study
Maria Eugenia Olmedo et al.
INVESTIGATIONAL NEW DRUGS (2021)
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
Fiona Blackhall et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Yun Fan et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer
Ming Chen et al.
NATURE COMMUNICATIONS (2021)
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage- SCLC: Results From the Phase 3 MERU Study
Melissa L. Johnson et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
OA11.04 Lurbinectedin With Irinotecan in Relapsed Small Cell Lung Cancer. Results From the Expansion Stage of a Phase I-II Trial
S. Ponce-Aix et al.
Journal of Thoracic Oncology (2021)
Overcoming Chemotherapy Resistance in SCLC
Brett H. Herzog et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Targeting the replication stress response through synthetic lethal strategies in cancer medicine
Natalie Y. L. Ngoi et al.
TRENDS IN CANCER (2021)
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L. Hart et al.
ADVANCES IN THERAPY (2021)
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
Neal E. Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
Hua Zhang et al.
CANCER CELL (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Harnessing Natural Killer Immunity in Metastatic SCLC
Sarah A. Best et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
Jose Trigo et al.
LANCET ONCOLOGY (2020)
Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)
Toufike Kanouni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization
Marina K. Baine et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial
Nathalie Baize et al.
LANCET ONCOLOGY (2020)
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
C. Allison Stewart et al.
NATURE CANCER (2020)
Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin
Remco Nagel et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study
Anish Thomas et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies
Junko Murai et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study
Yanjun Xu et al.
BRITISH JOURNAL OF CANCER (2019)
Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Daniel Morgensztern et al.
CLINICAL CANCER RESEARCH (2019)
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F. Farago et al.
CANCER DISCOVERY (2019)
Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
Wei Xie et al.
ONCOIMMUNOLOGY (2019)
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
J. M. Weiss et al.
ANNALS OF ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers
Carl M. Gay et al.
CLINICAL CANCER RESEARCH (2019)
The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer
Carminia M. Della Corte et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors
Sai-Wen Tang et al.
CLINICAL CANCER RESEARCH (2018)
A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
Paul Ponath et al.
CLINICAL CANCER RESEARCH (2018)
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Yu-Han Huang et al.
GENES & DEVELOPMENT (2018)
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
Anish Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
SLFN11 Blocks Stressed Replication Forks Independently of ATR
Junko Murai et al.
MOLECULAR CELL (2018)
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts
Benjamin J. Drapkin et al.
CANCER DISCOVERY (2018)
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
David M. Goldenberg et al.
Oncotarget (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
Alex H. Wagner et al.
NATURE COMMUNICATIONS (2018)
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Timothy L. Lochmann et al.
CLINICAL CANCER RESEARCH (2018)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
Marcello Tiseo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer
Jing Shan Lim et al.
NATURE (2017)
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
C. Allison Stewart et al.
ONCOTARGET (2017)
Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study
E. Calvo et al.
ANNALS OF ONCOLOGY (2017)
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Jhanelle E. Gray et al.
CLINICAL CANCER RESEARCH (2017)
Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
Cristina Belgiovine et al.
BRITISH JOURNAL OF CANCER (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Gurkan Mollaoglu et al.
CANCER CELL (2017)
SLFN11 inhibits checkpoint maintenance and homologous recombination repair
Yanhua Mu et al.
EMBO REPORTS (2016)
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
Vanesa Nogales et al.
ONCOTARGET (2016)
A DNA hypomethylation signature predicts novel antitumor activity of LSD1 inhibition in SCLC
Helai Mohammad et al.
CANCER RESEARCH (2016)
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
Kipp Weiskopf et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
Eric Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
John E. Bisi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs
Mark D. Borromeo et al.
CELL REPORTS (2016)
Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression
Eric Polley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary
Ryoko Takahashi et al.
PLOS ONE (2016)
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 inhibitors in SCLC
Helai P. Mohammad et al.
CANCER CELL (2015)
Lurbinectedin (PM01183) synergizes in vivo the antitumor activity of doxorubicin in SCLC tumor xenografts
Maria Jose Guillen et al.
CANCER RESEARCH (2015)
Different Levels of Twist1 Regulate Skin Tumor Initiation, Stemness, and Progression
Benjamin Beck et al.
CELL STEM CELL (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion
Ashish V. Kalra et al.
CANCER RESEARCH (2014)
Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer
Charles M. Rudin et al.
CLINICAL CANCER RESEARCH (2012)
LSD1 inhibition: a therapeutic strategy in cancer?
James T. Lynch et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
A Systematic Analysis of Efficacy of Second-Line Chemotherapy in Sensitive and Refractory Small-Cell Lung Cancer
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
Gabriele Zoppoli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A framework for identification of actionable cancer genome dependencies in small cell lung cancer
Martin L. Sos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
Lauren Averett Byers et al.
CANCER DISCOVERY (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells
Daniele G. Soares et al.
MOLECULAR CANCER THERAPEUTICS (2011)
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
Paul K. Paik et al.
LUNG CANCER (2011)
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
P. Zatloukal et al.
ANNALS OF ONCOLOGY (2010)
INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect
Alberto A. Chiappori et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
Trop2: A possible therapeutic target for late stage epithelial carcinomas
Rafael Cubas et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2009)
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Cyclin-dependent kinase 2-dependent phosphorylation of ATRIP regulates the G2-M checkpoint response to DNA damage
Jeremy S. Myers et al.
CANCER RESEARCH (2007)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
Mary E. R. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
DC Drummond et al.
CANCER RESEARCH (2006)
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
J Yang et al.
CELL (2004)
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
V Schreiber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer
W Noda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
ATR and ATRIP: Partners in checkpoint signaling
D Cortez et al.
SCIENCE (2001)
Share Paper
